CSIMarket
 
Delcath Systems Inc   (NASDAQ: DCTH)
Other Ticker:  
 
 
Price: $15.7500 $-0.22 -1.378%
Day's High: $16.05 Week Perf: -4.26 %
Day's Low: $ 15.60 30 Day Perf: 23.14 %
Volume (M): 244 52 Wk High: $ 16.97
Volume (M$): $ 3,835 52 Wk Avg: $8.66
Open: $15.60 52 Wk Low: $3.70



 Market Capitalization (Millions $) 509
 Shares Outstanding (Millions) 32
 Employees 40
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) -32
 Capital Exp. (TTM) (Millions $) 0

Delcath Systems Inc
Delcath Systems Inc is a medical technology company that specializes in the development and commercialization of products and therapies for the treatment of cancer. The company's main focus is on precision-targeted, whole organ chemotherapy, known as the Delcath Hepatic CHEMOSAT Delivery System. This system is designed to deliver high-dose chemotherapy directly to the liver while minimizing exposure to the rest of the body, thereby reducing toxic side effects. Delcath Systems Inc aims to improve patient outcomes and provide physicians with innovative treatment options for liver metastases.


   Company Address: 566 Queensbury Avenue Queensbury 12804 NY
   Company Phone Number: 489-2100   Stock Exchange / Ticker: NASDAQ DCTH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CLRB        4.13% 
HCA   -3.74%    
NEO        2.15% 
THC   -7.75%    
• View Complete Report
   



Business Update

Delcath Systems Strengthens Team with Strategic Inducement Grants to Drive Oncology Innovations,

Published Mon, Sep 23 2024 3:58 AM UTC

QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH) continues to demonstrate its commitment to fostering industry-leading talent as part of its broader strategy to advance treatments for primary and metastatic liver cancers. The interventional oncology company recently announced inducement grants under Nasdaq Listing Rule 5635(c)(4), signifying a strategic move to attra...

Business Update

Delcath Systems Driving Innovation in Liver Cancer Care Amid Strategic Workforce Expansion,

Published Sat, Sep 21 2024 12:47 AM UTC

Delcath Systems, Inc.: Advancements in Liver Cancer Treatment and Strategic Employment Inducements Delcath Systems, Inc. (NASDAQ: DCTH), based in Queensbury, New York, is carving a significant niche in the interventional oncology field, particularly focused on therapies targeting primary and metastatic cancers of the liver. Recent announcements from the company highlight its...

Business Update

Delcath Systems Inc. Adds Talent with Strategic Equity Awards to New Employees,

Published Fri, Sep 20 2024 8:47 PM UTC

QUEENSBURY, N.Y. In an assertive move to bolster its talented roster, Delcath Systems, Inc. (Nasdaq: DCTH), a leading interventional oncology company dedicated to the treatment of primary and metastatic cancers of the liver, disclosed the issuance of three distinct equity awards to new employees as part of its strategic growth plan. These inducement grants, sanctioned by t...

Business Update

Beam of Hope HEPZATO KIT Shines in New Data for Metastatic Uveal Melanoma Treatment at ESMO 2024,

Published Mon, Sep 16 2024 1:47 PM UTC

Promising New Data from Delcath Systems Highlights Efficacy of HEPZATO KIT in Treating Metastatic Uveal Melanoma SubgroupsIn a significant development for the oncology community, Delcath Systems, Inc. (Nasdaq: DCTH), an innovative company specializing in liver-directed cancer therapies, unveiled compelling new data at the European Society for Medical Oncology (ESMO) Congres...

Business Update

Pioneering Advances in Liver Cancer Treatment Delcath Systems? Innovative Approaches and Promising Financial Growth

Published Tue, Aug 27 2024 1:16 AM UTC

In the ever-evolving landscape of cancer treatment, few companies are making as significant an impact as Delcath Systems, Inc. (Nasdaq: DCTH). Based in Queensbury, New York, Delcath has emerged as a leading player in interventional oncology, particularly focused on treating primary and metastatic liver cancers. With recent promising results from independent studies and notew...







Delcath Systems Inc's Segments
CHEMOSAT    11.01 % of total Revenue
HEPZATO KIT    95.05 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com